WBA:NGS-Walgreens Boots Alliance Inc.

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 76.00

Change

+0.22 (+0.29)%

Market Cap

USD 75.29B

Volume

5.60M

Yahoo Analyst Target

USD 85.67 (12.72%)

STA Analyst Target

USD 85.82 (12.92%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Walgreens Boots Alliance Inc operates drug-stores chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug-stores, as well as mail, and by telephone and online.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
MYL Mylan N.V.

-0.27 (-0.58%)

USD 24.95B
NBIX Neurocrine Biosciences Inc.

+2.68 (+3.53%)

USD 6.95B
HCM Hutchison China MediTech Limit..

+0.25 (+0.63%)

USD 5.28B
AKRX Akorn Inc.

-0.09 (-0.27%)

USD 4.13B
GWPH GW Pharmaceuticals Plc

-0.45 (-0.34%)

USD 3.35B
HZNP Horizon Pharma plc

+0.22 (+1.47%)

USD 2.49B
IRWD Ironwood Pharmaceuticals Inc.

+0.10 (+0.67%)

USD 2.25B
SUPN Supernus Pharmaceuticals Inc.

-2.95 (-6.34%)

USD 2.23B
AERI Aerie Pharmaceuticals Inc.

+0.50 (+0.87%)

USD 2.13B
MDCO The Medicines Company

-0.34 (-1.34%)

USD 1.82B

ETFs Containing WBA

FCY:CA First Asset Cambridge Cor.. 5.86 % 0.89 %

+0.19 (+-0.14%)

CAD 3.69M
FCW:CA First Asset Cambridge Glo.. 4.98 % 0.00 %

N/A

CAD 1.01M
PMR PowerShares Dynamic Retai.. 4.69 % 0.63 %

+0.12 (+-0.14%)

USD 0.01B
RTH VanEck Vectors Retail 4.45 % 0.35 %

+0.16 (+-0.14%)

USD 0.07B
ICAN SerenityShares Impact 3.49 % 0.00 %

-0.04 (-0.14%)

N/A
FSTA Fidelity MSCI COnsumer St.. 3.24 % 0.08 %

-0.08 (-0.14%)

USD 0.35B
VDC Vanguard Consumer Staples 3.23 % 0.10 %

-0.53 (-0.14%)

USD 3.99B
SPVU PowerShares S&P 500 Enhan.. 2.13 % 0.25 %

-0.05 (-0.14%)

USD 0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.65% 53% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.65% 53% F 64% D
Trailing 12 Months  
Capital Gain -9.65% 39% F 24% F
Dividend Return 1.84% 100% A+ 44% F
Total Return -7.81% 39% F 24% F
Trailing 5 Years  
Capital Gain 93.83% 71% C- 61% D-
Dividend Return 11.26% 100% A+ 43% F
Total Return 105.09% 74% C 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 13.88% 66% D 63% D
Dividend Return 15.04% 67% D+ 62% D-
Total Return 1.17% 100% A+ 31% F
Risk Return Profile  
Volatility (Standard Deviation) 20.62% 94% A 64% D
Risk Adjusted Return 72.96% 96% A 71% C-
Market Capitalization 90.91B 100% A+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.82 8% F 32% F
Price/Book Ratio 2.74 55% F 41% F
Price / Cash Flow Ratio 2.67 21% F 47% F
Price/Free Cash Flow Ratio 12.65 18% F 41% F
Management Effectiveness  
Return on Equity 13.48% 82% B- 80% B-
Return on Invested Capital 12.66% 89% B+ 78% C+
Return on Assets 5.51% 88% B+ 80% B-
Debt to Equity Ratio 56.75% 35% F 42% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.